is there another name for tirzepatide Injection F.D.A. Approves New Obesity Drug

Some patients taking Wegovy may experience: Nausea or vomiting during bowel preparation Difficulty tolerating the full volume of preparation solution Variable bowel cleansing effectiveness To optimise bowel preparation, follow your endoscopy unit's specific instructions, which typically include: Split-dose regimens (taking part of the preparation the evening before and the remainder on the morning of the procedure) Clear guidance on when to stop eating solid foods (usually 24 hours before) Instructions on when you can last drink clear fluids (typically up to 2 hours before the procedure) Patient strategies to improve tolerance include: Taking the preparation solution slowly, sipping rather than gulping Keeping the solution chilled to improve palatability Using flavour packets if provided Remaining mobile during preparation to aid bowel transit Staying well-hydrated with permitted clear fluids If you experience severe vomiting, inability to complete the preparation, or signs of dehydration (dizziness, reduced urination, extreme thirst), contact your endoscopy unit or seek medical advice promptly

For retatrutide specifically, Phase 3 trial data are still being collected and analysed

Head-to-Head Efficacy Summary Retatrutide demonstrates superior weight loss efficacy based on Phase 2 data

Alcohol feels and functions the same as before tirzepatide

It remains the correct code for morbid or severe obesity due to excess calories with its longstanding clinical criteria

Lipids Health Dis 2011;10:217